Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SBC Medical Group Holdings (SBC) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Medical Group Holdings (SBC) over the last 3 years, with Q3 2025 value amounting to $127.4 million.

  • Medical Group Holdings' Cash & Equivalents fell 725.05% to $127.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.4 million, marking a year-over-year decrease of 725.05%. This contributed to the annual value of $125.0 million for FY2024, which is 2137.5% up from last year.
  • Medical Group Holdings' Cash & Equivalents amounted to $127.4 million in Q3 2025, which was down 725.05% from $152.7 million recorded in Q2 2025.
  • In the past 5 years, Medical Group Holdings' Cash & Equivalents ranged from a high of $152.7 million in Q2 2025 and a low of $217348.0 during Q1 2023
  • Over the past 3 years, Medical Group Holdings' median Cash & Equivalents value was $114.0 million (recorded in 2023), while the average stood at $78.2 million.
  • Data for Medical Group Holdings' Cash & Equivalents shows a peak YoY increase of 1092954.45% (in 2025) and a maximum YoY decrease of 725.05% (in 2025) over the last 5 years.
  • Medical Group Holdings' Cash & Equivalents (Quarter) stood at $103.0 million in 2023, then increased by 21.38% to $125.0 million in 2024, then rose by 1.91% to $127.4 million in 2025.
  • Its Cash & Equivalents stands at $127.4 million for Q3 2025, versus $152.7 million for Q2 2025 and $132.1 million for Q1 2025.